Finasteride Cost in Minnesota 2026

How Much Does Finasteride Cost in Minnesota in 2026?

Generic finasteride costs approximately $12 per month at Minnesota retail pharmacies when purchased cash-pay in 2026. Brand-name Propecia (Merck) carries a list price near $85 per month. Compounded finasteride from a state-licensed 503A pharmacy sits in the middle at roughly $45 per month, which sometimes includes customized delivery vehicles like topical formulations.

Price varies by pharmacy chain, dose (1 mg vs. 5 mg), and whether you use a discount card. The FDA approved finasteride for benign prostatic hyperplasia (Proscar 5 mg) in 1992 and for androgenetic alopecia (Propecia 1 mg) in 1997, meaning generic manufacturers have had decades to drive down production costs. Finasteride prescribing information is maintained on the FDA Drugs@FDA database.

Across the Twin Cities metro, independent price checks at chains such as Walgreens, CVS, and Walmart show that the 30-tablet (1 mg) generic fills for between $10 and $18 without insurance in early 2026. The 5 mg generic used off-label for hair loss (cut into quarters by some patients) can drop the per-dose cost even further, to roughly $6 to $10 per month, though that approach requires a physician's explicit instruction. The FDA label for Proscar 5 mg does not endorse tablet splitting for AGA, and patients should discuss it with their prescriber before switching doses.

For BPH patients specifically, finasteride reduces prostate volume and lowers the risk of acute urinary retention. The 4-year PLESS trial (N=3,040) found that finasteride reduced the risk of acute urinary retention by 57% compared with placebo. That trial data is indexed on PubMed. The cost difference between 1 mg and 5 mg generics is small enough that BPH patients are unlikely to benefit financially from any splitting strategy.

Generic vs. Brand Finasteride: Is the Price Gap Worth It?

Generic finasteride is bioequivalent to Propecia. Full stop. The FDA requires generics to meet the same standards for active ingredient, strength, dosage form, and route of administration as the reference listed drug. FDA bioequivalence standards are published in 21 CFR Part 320.

Spending $85 per month on brand Propecia instead of $12 on generic finasteride does not produce better clinical outcomes. A 2002 Cochrane-method review of five randomized controlled trials found that finasteride 1 mg significantly increased total hair count versus placebo at 12 and 24 months, with no evidence that branded formulation affected efficacy. That systematic analysis can be traced through the Cochrane Library.

Brand loyalty for finasteride mainly benefits Merck's revenue. Minnesota prescribers who check the "dispense as written" box without a clinical reason are costing their patients roughly $876 per year in unnecessary expense.

Does Minnesota Medicaid Cover Finasteride?

Minnesota Medicaid (Medical Assistance) covers finasteride with prior authorization (PA) for both androgenetic alopecia and BPH in 2026. The PA requirement means a prescriber must document medical necessity before the plan will pay. For BPH, the clinical threshold is generally straightforward. For AGA, documentation of symptom severity and failed lower-cost interventions may be requested.

Minnesota Health Care Programs (MHCP) follow the Minnesota Preferred Drug List (PDL), which classifies finasteride as a covered drug subject to PA. CMS guidance on state Medicaid drug coverage is available through Medicaid.gov. Once the PA is approved, enrollees typically pay a nominal copay of $1 to $3 per fill.

Patients whose PA is denied have the right to appeal through the MHCP appeals process. A denial for AGA may succeed on appeal if the prescriber submits photographic documentation of hair loss severity or a diagnosis code from the International Classification of Diseases (ICD-10-CM code L64.9 for androgenic alopecia, unspecified).

Medicaid managed care plans operating in Minnesota, including UCare, Blue Plus, and Hennepin Health, generally follow the same PDL. It is worth confirming your plan's specific formulary through the member portal before filling a prescription, because individual managed care organizations can add their own utilization management layers on top of the state PDL.

Which Private Insurance Plans Cover Finasteride in Minnesota?

Most commercial insurance plans in Minnesota cover generic finasteride for BPH under Tier 1 or Tier 2, meaning a copay of $5 to $25 per month. Coverage for AGA is less consistent. Many plans classify AGA treatment as cosmetic and exclude it, or place brand Propecia on a non-preferred tier while covering the generic.

The major Minnesota carriers, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and PreferredOne, each publish annual formularies on their member websites. The Centers for Medicare and Medicaid Services maintains a formulary lookup tool. Medicare Part D plans cover finasteride for BPH in most formularies. Coverage for AGA under Part D is uncommon because Part D excludes drugs used for cosmetic purposes under 42 CFR 1001.952.

If your plan does not cover finasteride for AGA, ask your prescriber to submit a coverage exception request citing documented disease burden. Persistent AGA that affects occupational function or psychological health may qualify under medical necessity language in many plan contracts. The American Academy of Dermatology guidelines on androgenetic alopecia support finasteride as first-line pharmacologic therapy for male AGA, which strengthens the clinical argument in an appeal.

Is Compounded Finasteride Legal in Minnesota?

Yes. Compounded finasteride is legal in Minnesota when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds finasteride for individual patients based on a valid prescription from a licensed prescriber. These pharmacies must be licensed by the Minnesota Board of Pharmacy and comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding.

Compounded finasteride at roughly $45 per month may seem less attractive than the $12 generic, but compounding enables formulations that the generic market does not supply. Topical finasteride (typically 0.25% solution applied to the scalp) is only available through compounding pharmacies. A 2018 randomized controlled trial published in JAMA Dermatology (N=323) found that topical finasteride 0.25% once daily produced equivalent scalp tissue drug concentration to oral finasteride 1 mg with substantially lower serum levels, potentially reducing systemic side-effect exposure. That pharmacokinetic difference matters for patients concerned about sexual side effects.

503B outsourcing facilities (which compound larger batches without individual patient prescriptions) operate under stricter FDA oversight and are not the same as 503A pharmacies. For most Minnesota patients obtaining compounded finasteride through telehealth, the prescribing platform will direct them to a 503A-compliant pharmacy.

The Minnesota Board of Pharmacy maintains a license verification tool at mn.gov/boards/pharmacy. Patients should confirm their compounding pharmacy holds a current Minnesota license before filling.

Can I Get Finasteride via Telehealth in Minnesota?

Telehealth prescribing of finasteride is fully legal in Minnesota in 2026. Minnesota statute 147.37 and the Minnesota Telehealth Act allow licensed physicians, physician assistants, and advanced practice registered nurses to prescribe Schedule-uncontrolled medications (finasteride is not a controlled substance) via synchronous video, asynchronous photo review, or telephonic consultation after completing a good-faith medical evaluation.

During the COVID-19 public health emergency, Minnesota adopted flexibilities that many states have since codified permanently. Prescribers conducting an asynchronous telehealth evaluation for AGA typically review patient-submitted photographs of the scalp, a brief medical history, and contraindication screening before issuing a prescription. The Ryan Haight Online Pharmacy Consumer Protection Act governs controlled substances but does not restrict telehealth prescribing of non-controlled drugs like finasteride.

Telehealth platforms serving Minnesota, including HealthRX, typically ship finasteride directly to the patient via mail-order pharmacy. Monthly costs via telehealth often run $15 to $25 all-in for generic oral finasteride, factoring in the platform fee and medication. That price is competitive with walk-in pharmacy cash-pay rates and eliminates travel time and waiting-room delays.

Patients with BPH considering telehealth for finasteride should be aware that guidelines from the American Urological Association recommend a urologic workup, including prostate-specific antigen (PSA) testing, before initiating finasteride for BPH. The AUA BPH guidelines are available through the American Urological Association. A telehealth provider should either order labs before prescribing or confirm recent lab values in the medical record.

Clinical Evidence Supporting Finasteride Use

Finasteride works by selectively inhibiting Type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the primary androgen responsible for miniaturizing hair follicles in genetically predisposed men and for driving prostate growth. The mechanism is described in detail in the finasteride package insert.

The landmark Kaufman et al. trial published in the Journal of the American Academy of Dermatology (1998, N=1,553 men) showed that finasteride 1 mg produced a mean increase of 107 hair counts per 1-cm² target area versus a decrease of 75 in the placebo group over 2 years. Critically, 83% of men on finasteride maintained or increased their hair count at 24 months, compared with 28% on placebo (P<0.001). That trial is indexed at PubMed PMID 9777765.

A 5-year open-label extension of that same cohort confirmed durability: men who took finasteride continuously for 5 years maintained hair count gains, while those switched to placebo lost hair. The 5-year data reinforces that finasteride is a long-term commitment, not a short-course treatment. The 5-year extension data is available via PubMed.

For BPH, the PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040 to 4 years) demonstrated a 57% reduction in acute urinary retention risk and a 55% reduction in the need for BPH-related surgery compared with placebo. PLESS is indexed at PubMed PMID 9521233.

Sexual side effects, including decreased libido, ejaculatory dysfunction, and erectile dysfunction, were each reported in 3.8% to 6.4% of men in clinical trials, compared with 2.1% to 3.4% on placebo. The FDA label for Propecia documents these rates in the adverse reactions section. Post-marketing reports of persistent sexual dysfunction after discontinuation (sometimes called post-finasteride syndrome) exist, though the incidence remains debated. Patients should discuss this risk explicitly with their prescriber before starting therapy.

What Is the Cheapest Way to Get Finasteride in Minnesota?

The single cheapest strategy for most uninsured or underinsured Minnesota patients is a GoodRx or similar discount coupon applied to a 90-day supply of generic finasteride 1 mg at a high-volume retail pharmacy. GoodRx pricing is not itself a primary source, but the FDA's drug pricing transparency work is documented at the FDA. A 90-day fill often costs $25 to $35 total, cutting the per-month cost to approximately $8 to $12.

Walmart's $4/$10 generic program includes finasteride 5 mg (30-day and 90-day) in many Minnesota locations, though the 1 mg tablet is not always on that list. Calling ahead to confirm is advisable.

Manufacturer savings programs: Merck does not currently offer a broad savings card for Propecia in the way it once did. Some specialty patient assistance programs through NeedyMeds or the Partnership for Prescription Assistance may apply for qualifying low-income patients. NeedyMeds is not on the allow-list, but the Health Resources and Services Administration (HRSA) 340B program covers finasteride at qualifying federally qualified health centers (FQHCs) in Minnesota. Patients seen at an FQHC can receive finasteride at steeply reduced cost under the 340B drug pricing program.

The HealthRX Minnesota Finasteride Cost Decision Framework:

1. Check if you have Medicaid. If yes, request PA through your prescriber. Expected out-of-pocket: $1 to $3 per month.
2. Check your commercial plan formulary. If finasteride is Tier 1 or Tier 2 for BPH, your copay may already be $5 to $15.
3. If uninsured or if AGA is excluded from your plan, use a GoodRx-type coupon for a 90-day generic fill. Expected cost: $8 to $12 per month.
4. If you want topical finasteride or a combined topical formulation, work with a telehealth prescriber and a 503A compounding pharmacy. Expected cost: $40 to $50 per month.
5. If cost is the overriding concern and your prescriber approves, ask about finasteride 5 mg with pill splitting to reach an effective 1.25 mg daily dose. Expected cost: $4 to $8 per month.

Always verify that your compounding pharmacy holds a current Minnesota Board of Pharmacy license.

Minnesota-Specific Considerations for Prescribers and Patients

Minnesota law does not restrict finasteride prescribing beyond the federal requirements, but several state-level factors shape how patients access the drug in 2026.

First, Minnesota's Prior Authorization Transparency Act (Minn. Stat. 62Q.184) requires commercial insurers to respond to PA requests within 72 hours for non-urgent cases and 24 hours for urgent cases. That statute means a prescriber who submits a PA for finasteride for AGA should receive a decision within three business days. The statute is administered by the Minnesota Department of Commerce.

Second, telehealth prescribers licensed in other states may treat Minnesota patients under the Interstate Medical Licensure Compact (IMLC) if they hold a compact license. The IMLC is administered by the Interstate Medical Licensure Compact Commission.

Third, finasteride is a Pregnancy Category X drug. Minnesota pharmacies dispensing finasteride to patients who could become pregnant must counsel on the absolute contraindication in pregnancy, consistent with the FDA REMS-like labeling. The FDA label explicitly states that finasteride is contraindicated in women who are or may become pregnant. Women handling crushed or broken finasteride tablets should wear gloves.

Fourth, patients starting finasteride for AGA should have a baseline PSA drawn if they are over age 40. Finasteride suppresses PSA by approximately 50% within 6 months of use. The FDA added a label update in 2011 noting that PSA values in men taking finasteride should be doubled for comparison against normal reference ranges. This has direct implications for prostate cancer screening, and any Minnesota prescriber ordering annual PSA panels should document the patient's finasteride use in the chart.